Trial · NCT06191744
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744, Phase 3, Active not recruiting, Genmab
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma. Trials, record NCT06191744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06191744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- NCT number
- NCT06191744
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 1,095 participants, actual
- Lead sponsor
- Genmab
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
- First posted
- 2024-01-05
- Last updated
- 2026-08-04
Source ClinicalTrials.gov
Registered outcomes96
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30) | Up to 30 Months | CR30 will be determined by positron emission tomography-computerized tomography (cat scan) \[PET-CT\] per Lugano 2014 criteria, as assessed by independent review committee (IRC). |
| Primary | Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS) | Up to 10 Years | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. |
| Secondary | Arm A1 vs Arm B: Overall Survival (OS) | Up to 10 Years | OS is defined as the time from the date of randomization to the date of death of any cause. |
| Secondary | Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate | Up to 10 Years | MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline. |
| Secondary | Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30) | 21 Weeks | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. |
| Secondary | Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30 | Up to 30 Months | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. |
| Secondary | Arm A1 vs Arm C: Percentage of Participants who Achieve CR30 | Up to 30 Months | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. |
| Secondary | Arm A1 vs Arm A2: Number of Participants with PFS | Up to 10 Years | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. |
| Secondary | Arm A1 vs Arm C: Number of Participants with PFS | Up to 10 Years | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. |
| Secondary | Arm A1 vs Arm A2: Rate of MRD Negativity | Up to 10 Years | MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline. |
1 to 10 of 96Source ClinicalTrials.gov
See all 96 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06191744
GET https://conductscience.org/api/trials/v1/NCT06191744/registered?page=2